Kenya attracts 13 new pharmaceutical manufacturers
Kenya has attracted 13 new pharmaceutical manufacturers to boost local production and reduce reliance on imports. The Pharmacy and Poisons Board is providing regulatory support to ensure these facilities meet international quality and safety standards.
Why it matters
Increasing local drug manufacturing is critical for Kenya's health security and economic independence, as the country currently imports the vast majority of its medical supplies.
Kenya has attracted 13 new pharmaceutical manufacturers that are at various stages of establishment and operationalisation, strengthening the country's efforts to expand local production of medicines and other health products. The new manufacturers are Med Aditus, Kenya Biovax Institute, Biopharma Limited in Gatundu-Thika, Full Care Limited, Tanatis Global Limited, Crown Healthcare, Regal Pharmaceuticals with its new penicillin plant, Spora International, Recon Health, the KEMRI Production Facility, Zuventus Limited, Aviazure Limited and Galaxy Pharmaceuticals. The companies are progressing through different stages of plant construction, equipment installation, quality-system development and regulatory readiness. Their entry signals growing investor interest in Kenya's pharmaceutical sector and its potential to serve both domestic and regional markets. The Pharmacy and Poisons Board (PPB) is providing regulatory guidance and technical support to facilitate the establishment of the facilities while ensuring that locally manufactured health products meet the required standards of quality, safety and efficacy.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in